Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Panacea Biotec Limited - Demise

1h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec collaborates with Serum Institute for new hexavalent vaccine for infants

2018-01-22 moneycontrol
Panacea Biotec in focus as the company has collaborated with Serum Institute of India for a new hexavalent vaccine for infants. In an interview with CNBC-TV18, Rajesh Jain, Joint Managing Director of the company discussed about the same.

Pharma weekly wrap: Pharma stocks extend loses ahead of Q3 results

2018-01-20 moneycontrol
Pharma stocks extended losses for the second consecutive week, ahead of the announcement of third-quarter results. The overall bullish sentiment prevalent in the stock market didn't rub off on pharma stocks. (72-0)

Panacea Biotech, Serum join hands to take ‘six-in-one’ vaccine global

2018-01-18 thehindubusinessline
Vaccine maker Panacea Biotec has entered into a collaboration with thr Serum Institute of India to take the former's fully liquid six-in-one vaccine onto a global stage, said Rajesh Jain, Panacea's Joint Managing Director.

Panacea and Serum Institute enter pact for hexavalent vaccine

2018-01-18 moneycontrol
Vaccine maker Panacea Biotec on Thursday said it has signed a pact with rival Serum Institute of India to source the critical Injectable Polio Vaccine (IPV) component from the latter for its own Hexavalent vaccine. (1-0)

Market Live: Banks lift Sensex over 350 pts; RBL, Federal, DCB other regional lenders may rally

2018-01-18 moneycontrol
12:50 pm Earnings: DB Corp's third quarter consolidated net profit fell 33.9 percent year-on-year to Rs 78.1 crore and revenue declined 4.6 percent to Rs 598.6 crore despite tax expenses declined to Rs 41 crore from Rs 59 crore. (48-0)

Panacea Biotech, Serum collaborate on six-in-one vaccine

2018-01-18 thehindubusinessline
Vaccine maker Panacea Biotec has signed two long-term agreements with Serum Institute of India and its wholly-owned subsidiary Bilthovan Biologicals BV, involving a fully liquid six-in-one vaccine. Under the collaboration, Serum will be allowed to make and sell fully liquid Whole cell Pertussis (wP) and Salk-based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed and commercialised by Panacea Biotec, touted to be the first of its kind, a joint note said.

Market Live: Banks lift Sensex over 300 pts; RBL, Federal, DCB other regional banks may rally

2018-01-18 moneycontrol
11:50 am Edelweiss on banks: A smooth passage of this proposal will pave the way for inclusion of HDFC Bank, IIB, Federal Bank, BoB and PNB in the Standard Index. It could also result in an increase in weights of existing standard constituents like ICICI Bank and State Bank of India, Edelweiss said in a report. (48-0)

Panacea Biotec surges 8% on signing 2 agreement with Serum Institute

2018-01-18 moneycontrol
Shares of Panacea Biotec added 8.6 percent intraday Thursday on signing two long term agreement with Serum Institute.

Panacea Biotec Limited - Press Release

2018-01-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - Spurt in Volume

2018-01-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - Spurt in Volume

2018-01-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - Credit Rating

2017-12-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

Panacea Biotec Limited - News Verification

2017-12-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.